Literature DB >> 10690529

Enhanced GBX2 expression stimulates growth of human prostate cancer cells via transcriptional up-regulation of the interleukin 6 gene.

A C Gao1, W Lou, J T Isaacs.   

Abstract

Previous studies demonstrated that the GBX2 homeobox gene is consistently overexpressed in cultured human prostate cancer cell lines. In this study, the human GBX2 cDNA was cloned and a quantitative reverse transcription-PCR method used to demonstrate that GBX2 mRNA expression is enhanced in approximately 70% of human prostate cancer tissues compared with normal human prostate tissues. Purified recombinant GBX2 protein binds specifically to an ATTA motif within the promoter of the interleukin 6 (IL-6) gene. Using an antisense approach, down-regulation of the expression of GBX2 correlated with decreased expression of IL-6 and an inhibition of tumorigenicity of PC3 human prostate cancer cells. In addition, in vitro growth of the antisense clones was partially restored by exogenous addition of recombinant IL-6 protein to the culture media. These data demonstrated that enhanced GBX2 expression results in a stimulation of malignant growth of prostate cancer cells and that part of this stimulation involves up-regulation in the transcription of the IL-6 gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690529

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  10 in total

1.  Stem cell-ness: a "magic marker" for cancer.

Authors:  John P Lahad; Gordon B Mills; Kevin R Coombes
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

2.  Oncogenic GBX2 promotes the malignant behaviors of bladder cancer cells by binding to the ITGA5 promoter and activating its transcription.

Authors:  Yaoyao Xiong; Xiaohang Song; Xiongbing Zu; Minfeng Chen; Wei He; Lin Qi
Journal:  Funct Integr Genomics       Date:  2022-06-08       Impact factor: 3.674

Review 3.  The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?

Authors:  Bernard Paule; Stéphane Terry; Laurence Kheuang; Pascale Soyeux; Francis Vacherot; Alexandre de la Taille
Journal:  World J Urol       Date:  2007-05-31       Impact factor: 4.226

4.  LncRNA FEZF1-AS1 accelerates the migration and invasion of laryngeal squamous cell carcinoma cells through miR-4497 targeting GBX2.

Authors:  Xudong Chen; Peng Cheng; Cihao Hu
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-07       Impact factor: 2.503

5.  Elongation factor 1 alpha1 and genes associated with Usher syndromes are downstream targets of GBX2.

Authors:  David A Roeseler; Shrikesh Sachdev; Desire M Buckley; Trupti Joshi; Doris K Wu; Dong Xu; Mark Hannink; Samuel T Waters
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

6.  Transcriptome profiling of cancer and normal tissues from cervical squamous cancer patients by deep sequencing.

Authors:  Wansong Lin; Mei Feng; Xiuhua Li; Peilin Zhong; Aihua Guo; Guilin Chen; Qin Xu; Yunbin Ye
Journal:  Mol Med Rep       Date:  2017-06-23       Impact factor: 2.952

7.  Bayesian variable selection for parametric survival model with applications to cancer omics data.

Authors:  Weiwei Duan; Ruyang Zhang; Yang Zhao; Sipeng Shen; Yongyue Wei; Feng Chen; David C Christiani
Journal:  Hum Genomics       Date:  2018-11-06       Impact factor: 4.639

8.  Transcriptomic analysis associated with reversal of cisplatin sensitivity in drug resistant osteosarcoma cells after a drug holiday.

Authors:  Divya Niveditha; Harshita Sharma; Syamantak Majumder; Sudeshna Mukherjee; Rajdeep Chowdhury; Shibasish Chowdhury
Journal:  BMC Cancer       Date:  2019-11-05       Impact factor: 4.430

9.  Menin mediates epigenetic regulation via histone H3 lysine 9 methylation.

Authors:  Y-J Yang; T-Y Song; J Park; J Lee; J Lim; H Jang; Y-N Kim; J-H Yang; Y Song; A Choi; H Y Lee; C H Jo; J W Han; S-T Kim; H-D Youn; E-J Cho
Journal:  Cell Death Dis       Date:  2013-04-11       Impact factor: 8.469

10.  Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.

Authors:  Tobias Kessler; Felix Sahm; Ahmed Sadik; Damian Stichel; Anne Hertenstein; Guido Reifenberger; Angela Zacher; Michael Sabel; Ghazaleh Tabatabai; Joachim Steinbach; Ulrich Sure; Dietmar Krex; Anca-L Grosu; Melanie Bewerunge-Hudler; David Jones; Stefan M Pfister; Michael Weller; Christiane Opitz; Martin Bendszus; Andreas von Deimling; Michael Platten; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 13.029

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.